Physician profile
Jericho L Bell
NPI 1811194772
$1,120.71
in general payments reported to CMS, 2019-2025
21 companies · $391 in 2025
The $391 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $30.05 · 2023: $196 · 2024: $504 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,090.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $189.32 | 2023-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $146.74 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Sumitomo Pharma America, INC. | $96.32 | 2024-2025 | Gemtesa |
| Novo Nordisk INC | $94.00 | 2023-2025 | Rybelsus, Ozempic, Tresiba |
| Exact Sciences Corporation | $71.68 | 2023-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $65.78 | 2025 | Korlym |
| Lilly USA, LLC | $59.04 | 2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $56.21 | 2024 | Breztri, Farxiga |
| Abbvie INC. | $50.00 | 2024-2025 | |
| Amgen INC. | $48.09 | 2025 | Repatha, Otezla |
| Pfizer INC. | $47.21 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.28 | 2023 | |
| Novartis Pharmaceuticals Corporation | $23.85 | 2025 | |
| Boston Scientific Corporation | $23.27 | 2025 | Wavewriter Alpha Prime 16 |
| Phathom Pharmaceuticals, INC. | $19.97 | 2024 | Voquezna |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.34 | 2025 | Xifaxan |
| Ironwood Pharmaceuticals, INC | $17.19 | 2023 | Linzess |
| Currax Pharmaceuticals LLC | $16.92 | 2023 | Contrave |
| Medtronic, INC. | $13.60 | 2025 | Vanta Adaptivestim |
| Lundbeck LLC | $13.51 | 2024 | Rexulti |
| Shield Therapeutics INC | $13.39 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jericho Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.